Guess those docs haven't heard or care about informed consent....

-----Original Message-----
From: [EMAIL PROTECTED]
[mailto:[EMAIL PROTECTED] Behalf Of Fritz, Donna
Sent: Thursday, December 22, 2005 3:05 PM
To: Mats Strömberg; Venous
Subject: RE: Spam: Breast cancer VAD choice


I'm addressing bullet point #3.  I think you will have to look at what chemo is 
giving in your area for breast ca treatment.  We're doing adriamycin + cytoxan, 
followed by a taxane, usually taxol.  It's usually given on an every 3 week 
basis for several months.  It seems an ideal circumstance for a port.

I think your line has to match the type of therapy patients will receive.  For 
colon patients receiving continuous 5FU, an externalized tunneled cath seems 
more suited.

Unfortunately, our physicians make the choice without presenting options to the 
patient, but this is kind of how they decide.  No evidence basis here.

Donna Fritz, RN, MN, OCN
Oncology CNS



-----Original Message-----
From: [EMAIL PROTECTED]
[mailto:[EMAIL PROTECTED] Behalf Of Mats Strömberg
Sent: Thursday, December 22, 2005 11:32 AM
To: Venous
Subject: Spam: Breast cancer VAD choice


Dear listers,

I am going to write about half a page on vascular access device choice for
breast cancer patients. It is part of a larger set of guidelines for breast
cancer.

The things I would like to address are:
- The importance of early assessment
- The advantages of central venous access devices (like better hemodilution
preserving the veins, lower risk for extravasation)
- The individual advantages of implanted ports, PICCs and Hickman lines
- When to opt for peripheral access

Is this the things that I should address?

I need to show the evidence base for everything. What is the evidence for
these things? What is the important litterature to use as references?

Thanks in advance
Mats in Stockholm

----
Mats Strömberg, RN, Research nurse
Dept. of Oncology
Karolinska University Hospital, Solna
SE-171 76 Stockholm

E-mail: [EMAIL PROTECTED]
Phone int: +46 8 517 76376
Mobile phone int: +46 70 471 6661





*****************************************************************************This
 communication is for the use of the intended recipient only.  It may contain 
information that is privileged and confidential.  If you are not the intended 
recipient of this communication, any disclosure, copying, further distribution 
or use thereof is prohibited.  If you have received this communication in 
error, please advise me by return e-mail or by telephone and delete/destroy 
it.*****************************************************************************







*************************************************************
The information contained in this E-mail transmission is 
intended only for the use of the individual or entity to whom 
it is addressed. It may contain privileged, confidential, 
and protected health information.

If you received it in error, you are on notice of its status. 
Please notify us immediately by reply e-mail and then please 
delete this message from your system.  Please do not copy it 
or use it for any purposes, or disclose its contents to any 
other person. To do so could violate state and Federal
privacy laws. Thank you for your cooperation.
Please contact the sender if you need assistance.

Reply via email to